Genetic screening with the DNA chip: a new Pandora's box?
Genetic screening with the DNA chip: a new Pandora's box?
复制标题
DOI：
10.1136/jme.25.2.200
复制
发表时间：
1999-04-01
影响因子：
4.1
通讯作者：
Henn, W
中科院分区：
文献类型：
--
作者：
Henn, W
由于方法学上的限制，非专利人群筛查这一在伦理上有争议的选择过去仅限于少数相当罕见的疾病，现在这些限制即将被克服。随着DNA微阵列(“DNA芯片”)这一新技术的出现，从微电子学和分子生物学的综合方法中涌现出一种新的方法，可用于开发针对广泛遗传特征的大规模筛选程序。因此，DNA芯片可能是精细化预防医学的关键技术，也可能是优生学的一个新维度。DNA芯片技术即将引入医疗实践，如果我们不希望它成为新的潘多拉盒子，就迫切需要一个国际上一致的道德标准和法律限制框架。
The ethically controversial option of generic population screening used to be restricted to a small number of rather rare diseases by methodological limitations which are now about to be overcome. With the new technology of DNA microarrays ("DNA chip"), emerging from the synthesis of microelectronics and molecular biology methods are low at hand for the development of mass screening programmes for a wide spectrum of genetic traits. Thus, the DNA chip may be the key technology for a refined preventive medicine as well as a new dimension of eugenics. The forthcoming introduction of the DNA chip technology into medical practice urgently requires an internationally consistent framework of ethical standards and legal limitations if we do not want it to become a new Pandora's box.